All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the latest updates to the Portuguese MM treatment guidelines?
Featured
The Multiple Myeloma Hub was pleased to speak to Rui Bergantim, Centro Hospitalar Universitário de São João, Porto, PT. We asked: What are the latest updates to the Portuguese multiple myeloma (MM) treatment guidelines?
What are the latest updates to the Portuguese MM treatment guidelines?
In this interview, Rui Bergantim opens by discussing the evolving MM treatment landscape, including novel drug combinations and approvals in Portugal. He highlights the latest recommendations in the first line, including combination treatments, as well as therapies for transplant conditioning and maintenance. Bergantim also goes on to discuss the management of relapsed/refractory MM, adapted by key factors such as cytogenetic abnormalities and frailty status.
Your opinion matters
18 votes - 52 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox